Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.

J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.

PMID:
31085763
2.

Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

Owen DH, Otterson GA.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4069-S4072. doi: 10.21037/jtd.2018.09.102. No abstract available.

3.

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.

Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA.

Clin Lung Cancer. 2018 Nov;19(6):e893-e900. doi: 10.1016/j.cllc.2018.08.008. Epub 2018 Aug 22.

4.

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.

Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, Abdel-Misih SRZ, Dillhoff ME, Sipos JA, Kirschner LS, Shah MH.

Oncotarget. 2017 Oct 24;8(61):104046-104056. doi: 10.18632/oncotarget.22001. eCollection 2017 Nov 28.

Supplemental Content

Loading ...
Support Center